For women who undergo fertility-sparing treatment for uterine cancer, subsequent use of fertility drugs is not associated with a higher incidence of cancer recurrence, according to research published in the January issue of Obstetrics & Gynecology.
Jeong-Yeol Park, MD, PhD, from the University of Ulsan College of Medicine in Seoul, South Korea, and colleagues examined pregnancy outcomes based on a review of the medical records of 141 women with Stage IA, Grade 1 endometrioid adenocarcinoma of the uterus who had complete remission after fertility-sparing management using progestin.
Of the cohort, 38.3% had a history of infertility. After treatment, the median interval to attempted pregnancy was five months, and at the time of the pregnancy trial, the median age was 32.4 years. The researchers found that 60 women (49.6%) tried to conceive, of which 62.9% received fertility drugs.